OV.25 Women with BRCA 1/2 mutation – Acetylsalicylic acid (ASA)
Main Inclusion criteria:
- Risk reducing surgery within 6 months to 2 years after the date of randomization
Main Exclusion criteria:
- Prior bilateral salpingectomy
- Prior treatment with PARP-inhibitors
[Details]